{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.05","upperLimit":"4.47","value":"2.14"},{"comment":"Upper limit of confidence interval could not be estimated due to an insufficient number of events.","groupId":"OG001","lowerLimit":"2.56","upperLimit":"NA","value":"4.24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"PFS: time between the date of administration of the first dose of the study drug and the date of the first documentation of progressive disease (PD) or death due to any cause (whichever occurred first) based on independent review of Efficacy and Safety Evaluation Committee, assessed by modified response criteria based on the revised response criteria for malignant lymphoma (Cheson, 2007), skin lesion and peripheral blood disease assessed according to clinical end points and response criteria in mycosis fungoides and Sezary syndrome (Olsen, 2011). PD: Any new lesion or unequivocally increase of previously involved sites from nadir. PFS was calculated using Kaplan-Meier method. Participants with no baseline assessments, treatment discontinuation without postbaseline tumor assessments, new anticancer treatment started prior to disease progression, death or PD after more than one missed tumor assessments and participants still on treatment without PD as of data cut-off were censored.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory PTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG000","title":"PTCL: E7777 9 mcg/kg/Day"},{"description":"Participants with CTCL received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG001","title":"CTCL: E7777 9 mcg/kg/Day"},{"description":"Participant with extranodal NK/T-cell lymphoma received E7777 9 mcg/kg/day as intravenous infusion, once daily from Day 1 through Day 5 in each treatment cycle until discontinuation or Cycle 8 (each Cycle length = 3 weeks).","id":"OG002","title":"Other: E7777 9 mcg/kg/Day"}],"paramType":"MEDIAN","populationDescription":"The FAS was defined as a group of participants who received at least 1 dose of the study drug.","reportingStatus":"POSTED","timeFrame":"From the date of administration of the first dose of the study drug until date of the first documentation of PD or death due to any cause (whichever occurred first) up to approximately 3 years 1 month","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}